FDA warned Fareva Amboise in France about sterile drug manufacturing failures, including aseptic practice and data integrity problems.
What happened
FDA inspected the Fareva Amboise drug manufacturing facility in Pocé-sur-Cisse, France, from September 8 to 16, 2025. FDA found inadequate airflow smoke studies, poor aseptic technique, process simulations (media fills) that did not simulate worst-case production, inadequate personnel monitoring, cleaning and disinfection gaps, and particle counter data integrity failures. FDA also found cleaning residues on non-dedicated equipment and said the company's responses lacked timelines, documentation, and product-impact assessments.
What FDA found
FDA said smoke studies on the Grade A aseptic filling line did not show unidirectional airflow and revealed poor airflow patterns and aseptic practices.
21 CFR 211.113(b)FDA said operators used poor aseptic technique, and process simulations (media fills) did not simulate worst-case commercial operations or document interventions.
21 CFR 211.113(b)FDA said personnel whose hands or forearms entered Grade A were held to Grade B monitoring limits, and it found no adequate investigation after Corynebacterium was recovered on an operator's forearm.
21 CFR 211.113(b)FDA said the company lacked adequate contamination controls, including cleaning and disinfection of Grade A surfaces and equipment such as a stopper bowl that could not be disassembled.
21 CFR 211.42(c)(10)(v)FDA said particle counters allowed users to change dates and alarm limits, failing results were not kept in batch records, and data was deleted without backups.
21 CFR 211.68(b)FDA said cleaning of non-dedicated equipment was inadequate, with residues observed and an active pharmaceutical ingredient detected in a sample.
21 CFR 211.67(a)
What FDA wants
FDA asks Fareva to provide a comprehensive contamination-hazard risk assessment and remediation plan with timelines, dynamic smoke studies, a remediated media-fill program, retrospective product-impact reviews, cleaning and disinfection validation, equipment CAPA, and an independent computer-system assessment with interim controls. The letter does not state a response deadline.
Who should pay attention
- brands that buy sterile animal or human drugs from this contract manufacturer
- companies whose products are filled on the affected aseptic line
- quality teams relying on Fareva Amboise batch and particle-count records
This is a summary. Read the original letter on fda.gov.